ADMA Biologics (ADMA) Stock: Buy, Sell, or Hold?
ADMA - ADMA Biologics, Inc.
$9.23
-0.16 (-1.70%)
▼
5d:
-3.65%
30d:
-5.62%
90d:
+10.94%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 04, 2026
Get Alerted When ADMA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: ADMA shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: ADMA shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$21.78
Based on 13.7% avg growth
INTRINSIC VALUE TODAY
$13.53
31.8% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 11.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ADMA is currently trading at $9.23, which is considered oversold relative to its 30-day fair value range of $9.24 to $9.83. From a valuation perspective, the stock is trading at a discount (Forward PE: 9.4) compared to its historical average (11.8). Remarkably, the market is currently pricing in an annual earnings decline of 7.3% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ADMA is in a strong downtrend. The price is currently testing key support at $9.20. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 44/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $17.00 (+84.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ADMA is in a strong downtrend. The price is currently testing key support at $9.20. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 44/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $17.00 (+84.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$9.24 -
$9.83
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
Protect Your Profits
Holding ADMA? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (44/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 84.2% below Wall St target ($17.00)
- WARNING: Composite score 44/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$9.24 -
$9.83
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$9.20
Resistance Level
$9.65
Current Trend
Strong Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
9.39
Wall Street Target
$17.00
(+84.2%)
Revenue Growth (YoY)
15.9%
Earnings Growth (YoY)
-52.8%
Profit Margin
33.0%
Valuation Discount vs History
-7.3% cheaper
PE vs Historical
9.4 vs 11.8
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-7.3%
(market-implied from PE analysis)
1-Year Target
$8.56
(-7%)
2-Year Target
$7.93
(-14%)
3-Year Target
$7.35
(-20%)
3-Yr Target (if PE normalizes)
(PE: 9→12)
$9.24
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.2, Growth: 23.3%)
$37.17
(+303%)
Base:
(SPY PE: 9.4, Growth: 23.3%)
$17.31
(+88%)
Bear:
(PE: 8.0, Growth: 23.3%)
$14.71
(+59%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (13x PE), but valuation improves significantly next year (9x PE) as earnings recover.
Trailing PE: 13.41 | Current EPS (TTM): $0.70
Bull Case
$14.50
(+57%)
Analyst growth 40.4%, PE expands to 14.8
Base Case
$13.18
(+43%)
Market implied 40.4%, PE stable at 13.4
Bear Case
$6.39
(-31%)
Severe decline -20.0%, PE contracts to 11.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 9.4 to 11.8
Stabilization Target:
$11.59
(+25.6%)
PE Expansion Potential:
+25.6%
Share & Embed Analysis
Last updated: September 11, 2026 9:04 PM ET
Data refreshes hourly during market hours. Next update: 10:04 PM
Data refreshes hourly during market hours. Next update: 10:04 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ADMA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 58 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 56 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$49 | 44 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 60 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 57 HOLD |
Advanced ADMA Option Strategies
Professional options setups generated by AI based on today's ADMA price and gamma walls.
